Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02513784 · ClinicalTrials.gov registry record · NA

Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome

A NA study of Esophageal Adenocarcinoma and Barrett's Esophagus, sponsored by Columbia University.

Completed
Registry status
NA
Development phase
20
Enrollment target
1
Study location

NCT02513784 is a NA study of Esophageal Adenocarcinoma and Barrett's Esophagus that has completed, run by Columbia University. The registered enrollment target is 20 participants, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (94% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02513784, a NA study of Esophageal Adenocarcinoma and Barrett's Esophagus, has completed, sponsored by Columbia University.

COMPLETED
Registry status
NA
Development phase
20 participants
Enrollment target
1
Study location

Study Summary

This is a randomized, open-label pilot study to assess whether treatment with chlorhexidine mouthwash can alter the esophageal and gastric cardia microbiome

Interventions

  • DRUG Chlorhexidine gluconate

Study Locations (1)

New York

  • Columbia University Medical Center - New York

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2015-08
Est. Completion 2017-12
Phase NA

Sponsor

Columbia University

958 total trials

What the Registry Record Tells You About NCT02513784

The ClinicalTrials.gov registry entry for NCT02513784 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 20 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 308-participant average among 43 other Esophageal Adenocarcinoma trials with a reported enrollment target (94% lower). The listed sponsor is Columbia University, which has 958 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Esophageal Adenocarcinoma appearing as the primary indexed condition, and to 1 intervention - of which Chlorhexidine gluconate is the first listed.

NCT02513784 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT02513784 about?

NCT02513784 is a clinical study titled "Trial to Assess the Effects of an Antimicrobial Mouthwash on the Esophageal Microbiome". This is a randomized, open-label pilot study to assess whether treatment with chlorhexidine mouthwash can alter the esophageal and gastric cardia microbiome

What is the current status of trial NCT02513784?

This trial is currently completed. It is a NA study. The enrollment target is 20 participants. The study started on 2015-08. Estimated completion is 2017-12.

What conditions does trial NCT02513784 study?

This clinical trial studies the following conditions: Esophageal Adenocarcinoma, Barrett's Esophagus, Reflux Esophagitis.

What interventions are being tested in trial NCT02513784?

The interventions under investigation include: Chlorhexidine gluconate (DRUG).

Who is sponsoring clinical trial NCT02513784?

This trial is sponsored by Columbia University, which has 958 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02513784 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Esophageal Adenocarcinoma

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.